The immunologic response to severe acute respiratory syndrome coronavirus 2
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated the worst global pandemic in a century, which has caused millions of infections and deaths as well as massive economic repercussions.
Objective:
As with any pathogenic virus, it is crucial to understand its unique interactions with the human immune system so that pharmaceutical and prophylactic interventions can be deployed to effectively control the pandemic.
Methods:
A literature search by using PubMed was conducted in 2020 with variants of the terms “COVID-19,” “SARS-CoV-2,” and “immunological response.” English language articles that presented original data about the immunologic response to coronavirus disease 2019 (COVID-19) were selected for review. This article reviewed the current understanding of the innate and adaptive immune responses to SARS-CoV-2 infection, including their relationship to current therapeutic and diagnostic strategies.
Results:
SARS-CoV-2 uses several unique molecular techniques to evade detection by the innate immune system early in the course of infection, and upregulation of these innate immune pathways may possibly accelerate the time to recovery and prevent severe disease. Although the majority of cases results in the patients' recovery, a significant proportion of infections result in deaths prompted by the host's inflammatory overreaction to the infection, a response that can be attenuated with corticosteroids and potentially other immune modulators.
Conclusion:
Current work by the scientific community to further understand how SARS-CoV-2 interacts with the human immune system will be invaluable to our response and preparedness for future coronavirus pandemics.
Keywords: COVID-19; Coronavirus; Immunological response; SARS-CoV-2; adaptive immune system; angiotensin-converting enzyme 2; innate immune system; severe acute respiratory syndrome coronavirus 2; spike protein; viruses
Document Type: Research Article
Affiliations: 1: From the Department of Surgery, Morsani College of Medicine, University of South Florida, Tampa, Florida; 2: Divison of Rheumatology, Allergy and Immunology, Yale University School of Medicine, New Haven, Connecticut; 3: Division of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, Massachusetts; 4: Division of Allergy and Immunology, Children's National Hospital, Washington, D.C.; 5: Department of Anatomical Science and Education, Saint Louis University School of Medicine, St. Louis, Missouri; 6: Division of Laboratory Medicine, Children's National Hospital, Washington, D.C.; 7: Division of Global Communicable Disease, College of Public Health, University of South Florida, Tampa, Florida; and
Publication date: November 1, 2021
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service. - Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Commercial level: Permission to use content
- www.JFoodAllergy.com
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content